RECCE PHARMACEUTICALS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.61 AUD | 0.00% |
|
-6.15% | +14.02% |
| May. 15 | Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial | MT |
| May. 10 | Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 158.1 | 111.4 | 124.4 | - | - |
| Enterprise Value (EV) 1 | 158.1 | 113 | 124.6 | 120.9 | 120.5 |
| P/E ratio | -14.1 x | -8.31 x | -8.13 x | -3.69 x | -14.5 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 25.8 x | 18 x | 21.8 x | 40.1 x |
| EV / Revenue | - | 26.2 x | 18 x | 21.2 x | 38.9 x |
| EV / EBITDA | - | -8.83 x | -9.51 x | -3.98 x | -12.6 x |
| EV / FCF | - | -8.88 x | -9.5 x | -3.64 x | -12.6 x |
| FCF Yield | - | -11.3% | -10.5% | -27.5% | -7.96% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 177,647 | 178,254 | 203,987 | - | - |
| Reference price 2 | 0.8900 | 0.6250 | 0.6100 | 0.6100 | 0.6100 |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 4.311 | 6.928 | 5.696 | 3.1 |
| EBITDA 1 | - | -12.8 | -13.11 | -30.42 | -9.6 |
| EBIT 1 | - | -12.69 | -13.35 | -30.63 | -9.6 |
| Operating Margin | - | -294.33% | -192.7% | -537.82% | -309.68% |
| Earnings before Tax (EBT) 1 | - | -13.08 | -13.57 | -33.36 | -9.6 |
| Net income 1 | -10.99 | -13.08 | -13.57 | -33.36 | -9.6 |
| Net margin | - | -303.34% | -195.85% | -585.6% | -309.68% |
| EPS 2 | -0.0631 | -0.0752 | -0.0750 | -0.1655 | -0.0420 |
| Free Cash Flow 1 | - | -12.73 | -13.12 | -33.21 | -9.6 |
| FCF margin | - | -295.18% | -189.38% | -583% | -309.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 1.56 | 0.2 | - | - |
| Net Cash position 1 | - | - | - | 3.5 | 3.9 |
| Leverage (Debt/EBITDA) | - | -0.122 x | -0.0153 x | - | - |
| Free Cash Flow 1 | - | -12.7 | -13.1 | -33.2 | -9.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | -0.0700 | -0.0400 | -0.0400 |
| Capex 1 | - | 0.04 | 0.12 | 0.13 | - |
| Capex / Sales | - | 0.9% | 1.72% | 2.3% | - |
| Announcement Date | 8/31/22 | 8/31/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.02% | 83.16M | |
| +35.01% | 709B | |
| +31.11% | 595B | |
| -2.60% | 367B | |
| +20.83% | 334B | |
| +5.69% | 289B | |
| +14.49% | 239B | |
| +9.43% | 211B | |
| -4.21% | 203B | |
| +10.77% | 171B |
- Stock Market
- Equities
- RCE Stock
- Financials Recce Pharmaceuticals Ltd